For the year ending 2025-12-31, SBFM made $36,305,891 in revenue. -$5,210,702 in net income. Net profit margin of -14.35%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Revenue | 36,305,891 | 34,874,283 | ||
| Cost of sales | 24,050,214 | 24,204,489 | ||
| Gross profit | 12,255,677 | 10,669,794 | ||
| Accounting | 698,083 | 967,614 | ||
| Consulting | 1,571,692 | 925,188 | ||
| Director fees | 400,000 | 400,000 | ||
| Intangible assets impairment | 1,748,247 | - | ||
| Legal | 385,142 | 875,698 | ||
| Marketing | 1,143,929 | 940,278 | ||
| Office | 3,864,584 | 3,110,026 | ||
| R&d | 604,308 | 933,902 | ||
| Salaries | 7,265,346 | 7,718,677 | ||
| Taxes | 469,305 | 387,005 | ||
| Depreciation & amortization | 332,070 | 223,527 | ||
| Total general & administrative expenses | 18,482,706 | 16,481,915 | ||
| (loss) from operations | -6,227,029 | -5,812,121 | ||
| Foreign exchange gain (loss) | 2,642 | -44,082 | ||
| Interest income | 280,901 | 496,003 | ||
| Interest expense | 0 | 8,774 | ||
| Gain (loss) on asset sale | -10,257 | - | ||
| Total other income (expense) | 273,286 | 443,147 | ||
| Net (loss) before income taxes | -5,953,743 | -5,368,974 | ||
| Provision for income taxes | 21,609 | -234,858 | ||
| Net (loss) | -5,975,352 | -5,134,116 | ||
| Gain (loss) from foreign exchange translation | 764,650 | -1,526,064 | ||
| Comprehensive (loss) | -5,210,702 | -6,660,180 | ||
| Basic EPS | -1.44 | -7.32 | ||
| Diluted EPS | - | -7.32 | ||
| Basic Average Shares | 4,157,086 | 701,749 | ||
| Diluted Average Shares | - | 701,749 | ||
Sunshine Biopharma Inc. (SBFM)
Sunshine Biopharma Inc. (SBFM)